OSCR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Oscar Health Inc (OSCR) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. Despite the pre-market dip, the company's improving financials, positive analyst sentiment, and attractive valuation make it a compelling long-term opportunity.
The MACD is positive and expanding, indicating bullish momentum. RSI is neutral at 60.118, suggesting no overbought or oversold conditions. The stock is trading near its pivot point of 13.499, with resistance levels at 14.849 and 15.684, and support levels at 12.148 and 11.314. Converging moving averages indicate a potential trend reversal or continuation.
Analysts have upgraded the stock recently, with Raymond James upgrading to Outperform and setting an $18 price target.
The company's financials show significant YoY improvement in revenue (+17.30%) and net income (+129.64%).
The stock is seen as attractively valued by analysts, with potential for margin recovery in the Affordable Care Act exchange market.
Pre-market price drop of -2.64%, which may indicate short-term bearish sentiment.
UBS recently lowered its price target to $15, citing a neutral stance.
No recent news or significant trading trends from insiders or hedge funds.
In Q4 2025, revenue increased by 17.30% YoY to $2.81 billion. Net income improved significantly, up 129.64% YoY, though still negative at -$352.61 million. EPS improved to -1.24, up 100% YoY. Gross margin remained at 0%. The company is showing signs of financial recovery.
Analyst sentiment is generally positive, with multiple upgrades in recent months. Raymond James upgraded to Outperform with an $18 price target, citing attractive valuation and margin recovery. UBS downgraded to Neutral but still sees the stock fairly priced at $15. Barclays upgraded to Equal Weight with an $18 price target, highlighting potential margin expansion.
